Target enzyme activity as a biomarker for immunosuppression

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 257-260

  Glander, Petra ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcineurin activity; Immunosuppression; IMPDH activity; MTOR inhibitors; Pharmacodynamics

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE NUCLEOSIDE; TACROLIMUS;

ANALYTIC METHOD; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; ORGAN TRANSPLANTATION; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN TARGETING; REPRODUCIBILITY;

BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MYCOPHENOLIC ACID; OXIDOREDUCTASES;

EID: 77952953702     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ddd7b3     Document Type: Conference Paper

References (47)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729.
2. Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol. 2003;3:831-838.
3. Kuypers DR. Immunosuppressive drug monitoring\what to use in clinical practice today to improve renal graft outcome. Transpl Int. 2005; 18:140-150.
4. Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother. 2003;4:2325-2345.
5. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004; 5:1333-1345.
6. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiprolifer-ative and immunsuppressive activity of mycophenolic acid and its mor-pholinoethyl ester (RS-61443) in rodents. Transpl Proc. 1991;23:15-18.
7. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with myco-phenolate mofetil: review of the literature. Transplantation. 2006;82: 1004-1012.
8. Knight SR, Morris PJ. Does the evidence support the use of myco-phenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675-1685.
9. de Winter BC, Mathôt RA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol. 2007;3:251-261.
10. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28: 145-154.
11. Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007;2:184-191.
12. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosup-pressive drugs. Curr Opin Immunol. 2000,12:557-562.
13. Yatskoff RW, Aspeslet LA, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem. 1998;44: 428-432.
14. Oellerich M, Barten MJ, Armstrong VW. Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit. 2006;28:35-38. (Pubitemid 44391691)
15. Burkhart C, Heusser C, Morris RE, et al. Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit. 2004; 26:588-592.
16. Brunet M, Campistol JM, Diekmann F, et al. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther. 2007;11:247-256.
17. Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab Pharmacokinet. 2008;23:150-157.
18. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA. 1992;89:3686-3690.
19. Enz A, Shapiro G, Chappuis A, et al. Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal Biochem. 1994;216:147-153.
20. Blanchet B, Hulin A, Duvoux C, et al. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem. 2003;312:1-6.
21. de Jonge H, Naesens M, Kuypers DR. New insights into the pharma-cokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31:416-435.
22. Hartmann B, Schmid G, Graeb C, et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int. 2005;68:2593-2598.
23. Leogrande D, Teutonico A, Ranieri E, et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2007;50: 314-325.
24. Balzarini J, De Clercq E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes. Biochem J. 1992;287:785-790.
25. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
26. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
27. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int. 2000;13(Suppl 1):S301-S305.
28. Montero C, Duley JA, Fairbanks LD, et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method. Clin Chim Acta. 1995;238:169-178.
29. Griesmacher A, Weigel G, Seebacher G, et al. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem. 1997;43:2312-2317.
30. Albrecht W, Storck M, Pfetsch E, et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit. 2000;22: 283-294.
31. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549.
32. Sanquer S, Maison P, Tomkiewicz C, et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008;83:328-335.
33. Vethe NT, Bergan S. Determination of inosine monophosphate de-hydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit. 2006;28:608-613.
34. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476.
35. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
36. Budde K, Glander P, Krämer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation. 2007;83:417-424. (Pubitemid 46667845)
37. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmaco-dynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898. (Pubitemid 46481185)
38. Glander P, Sombogaard F, Budde K, et al. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydroge-nase activity in peripheral blood mononuclear cells. Ther Drug Monit. 2009;31:351-359.
39. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109:2903-2928.
40. Devyatko E, Zuckermann A, Bohdjalian A, et al. Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. Transplantation. 2006;82:113-118.
41. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol. 2004;67:767-776.
42. Kamar N, Glander P, Nolting J, et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin J Am Soc Nephrol. 2009;4:936-942.
43. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med. 2000;38:1213-1216.
44. Haglund S, Taipalensuu J, Peterson C, et al. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease\relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008;65:69-77.
45. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T.C polymorphism. Pharmacogenet Ge-nomics. 2009;19:626-634.
46. Sombogaard F, Peeters AM, Baan CC, et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit. 2009;31:549-656.
47. Grinyó J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008;21:879-891.